Effect of Tulathromycin on Colonization Resistance, Antimicrobial Resistance, and Virulence of Human Gut Microbiota in Chemostats by Haihong Hao et al.
ORIGINAL RESEARCH
published: 08 April 2016
doi: 10.3389/fmicb.2016.00477
Frontiers in Microbiology | www.frontiersin.org 1 April 2016 | Volume 7 | Article 477
Edited by:
Alexandre Gonçalves,
University of Trás-os-Montes e Alto
Douro, Portugal
Reviewed by:
Atte Von Wright,
University of Eastern Finland, Finland
Jian-Hua Liu,
South China Agricultural University,
China
*Correspondence:
Yulian Wang
wangyulian@mail.hzau.edu.cn;
Zonghui Yuan
yuan5802@mail.hzau.edu.cn
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 07 January 2016
Accepted: 22 March 2016
Published: 08 April 2016
Citation:
Hao H, Zhou S, Cheng G, Dai M,
Wang X, Liu Z, Wang Y and Yuan Z
(2016) Effect of Tulathromycin on
Colonization Resistance, Antimicrobial
Resistance, and Virulence of Human
Gut Microbiota in Chemostats.
Front. Microbiol. 7:477.
doi: 10.3389/fmicb.2016.00477
Effect of Tulathromycin on
Colonization Resistance,
Antimicrobial Resistance, and
Virulence of Human Gut Microbiota in
Chemostats
Haihong Hao 1, 2 †, Shengxi Zhou 2†, Guyue Cheng 2, Menghong Dai 2, Xu Wang 1, Zhenli Liu 1,
Yulian Wang 1, 2* and Zonghui Yuan 1, 2*
1National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug
Residues, Huazhong Agricultural University, Wuhan, China, 2MOA Laboratory for Risk Assessment of Quality and Safety of
Livestock and Poultry Products, Huazhong Agricultural University, Wuhan, China
To evaluate microbiological safety of tulathromycin on human intestinal bacteria,
tulathromycin (0, 0.1, 1, 10, and 100 µg/mL) was added into Chemostats. Before
and after drug exposure, we monitored (1) population, SCFA products, antimicrobial
resistance, and colonization resistance of gut microbiota, and (2) the antimicrobial
resistance genes, transferability, virulent genes, pathogenicity of Enterococus faecalis.
Results showed that low level of tulathromycin did not exhibit microbiological hazard
on resistance selection and colonization resistance. However, high level of tulathromycin
(10 and 100 µg/mL) may disturb colonization resistance of human gut microbiota and
select antimicrobial resistant E. faecalis. Most of the selected resistant E. faecalis carried
resistant gene of ermB, transferable element of Tn1545 and three virulence genes (esp,
cylA, and ace). One of them (E. faecalis 143) was confirmed to have higher horizontal
transfer risk and higher pathogenicity. The calculated no observable adverse effect
concentration (NOAEC) and microbiological acceptable daily intake (mADI) in our study
was 1 µg/mL and 14.66 µg/kg.bw/day, respectively.
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INTRODUCTION
Tulathromycin is the first and onlymember of the triamilide sub-class of macrolide. Tulathromycin
is used therapeutically in treatment of respiratory disease in swine and cattle at a single dose of 2.5
mg/kg.bw. It has been registered in more than 30 countries across America, Europe, Oceania, and
Asia and played important role in veterinary medicine (FDA, 2004). This agent is characterized by
rapid absorption from the injection site, extensive distribution to tissue, and slow elimination. The
withdrawal period for cattle and swine is 22 and 5 days, respectively. This drug is excreted primarily
unchanged (90%) in feces (2/3) and in urine (1/3), suggesting that it may reach to human colon and
remain its antimicrobial activity (Benchaoui et al., 2004; EMEA, 2004; Nowakowski et al., 2004).
The residue of tulathromycin in animal food may have unintended microbiological effects on
human gut microbiota. The possible harmful effects may be: (1) shifts in bacterial counts and
biochemistry, (2) destruction of colonization resistance, (3) emergence of antimicrobial resistant
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bacteria (Cerniglia and Kotarski, 1999; Nutsch et al., 2005).
Additionally, antibiotic resistant bacteria may have enhanced
fitness or high virulence (Mundy et al., 2000). Human intestinal
strains may also serve as reservoirs for antimicrobial resistant
determinations and mediates the gene transfer (Salyers et al.,
2004).
Based on in vitro antibiotic susceptibility tests,
microbiological ADIs recommended by Food and Drug
Administration (FDA), European Medicine Agency (EMA),
and Australian Pesticides and Veterinary Medicines Authority
(APVMA) were 50, 10.99, and 5 µg/kg.bw/d, respectively. The
large difference in these mADI may due to the disadvantage
and limitation of short-term in vitro antibiotic susceptibility
tests in evaluation of long-term effects of tulathromycin residues
posed on human intestinal bacteria and in analyze of impact
of tulathromycin on colonization resistance and emergence
of antimicrobial resistance of human colonic microbiota
(Cerniglia and Kotarski, 2005). Therefore, microbiological
safety assessment measures of tulathromycin residues is largely
inadequate. It is largely unknown that what is the effect of
long-term exposure to tulathromycin on colonization resistance
of human intestinal microbiota and on antimicrobial resistance
development, virulence change, and gene transfer in some
specific intestinal bacteria.
In the present article, the chemostat model of human colonic
gut, which is an approach recommended by VICH (VICH GL-
36) and some previous studies (Carman and Woodburn, 2001;
Carman et al., 2004, 2005), is used to evaluate microbiological
safety of tulathromycin on human intestinal microbiota.
MATERIALS AND METHODS
Chemicals
The tulathromycin (TUL), erythromycin (ERY), and lincomycin
(LIN) were dissolved in methanol and then diluted with
deionized water. The ciprofloxacin (CIP), tetracycline
(TET), and rifampicin (RIF) were dissolved in deionized
water. Tulathromycin was purchased from Liu He animal
Pharmaceutical Co., Ltd. (Qingdao, China). The erythromycin,
lincomycin, ciprofloxacin, tetracycline, and rifampicin were
purchased from SIGMA.
Bacteria Strains
The E. coli ATCC 25922, Enterococcus faecalis ATCC29212,
and Micrococcus luteus ATCC 9341 were purchased from
American Type Culture Collection (ATCC). The E. coli ATCC
25922 and E. faecalis ATCC29212 were used as quality
controls for species identification and minimum inhibitory
concentration (MIC) determination. The M. luteus ATCC
9341 were used as an indicator for determination of the
concentration of tulathromycin. E. faecalis JH2-2 (Rifampicin
MIC > 50 µg/mL) and E. coli NK5449 (Rifampicin MIC >
100 µg/mL), purchased from Belgian coordinated collections
of microorganisms and Institute of microbiology in Chinese
academy of sciences, respectively, were used as receptors
for conjugation test. The Salmonella Typhimurium SI3 was
a ciprofloxacin resistant strain which was selected in our
previous study (Sun et al., 2011). This strain was used as the
challenge strain for evaluating the colonization resistance of
chemostat.
Preparation of Fresh Fecal Samples and
Strain Isolation
Fresh fecal samples from six adult volunteers who had no history
of antibiotic usage and gastrointestinal disturbance within the
preceding 3 months were prepared following previous method
(Carman and Woodburn, 2001; Hao et al., 2013). The use of
human fecal samples was approved by the ethical Committee
of Huazhong Agricultural University (approval number hzauch
2013-002).
Strain Isolation and MIC Determination
from Fresh Fecal Samples
The four predominant intestinal bacteria (E. coli, Enterococcus,
Bifidobacterium, and Bacteroides fragilis) were isolated from the
fresh fecal samples of six adult volunteers by selective agars
(Eosin methylene blue agar, bile esculin azide agar, BBL media,
and bacteroides bile esculin agar). Ten isolates of each species
were obtained from fresh fecal sample of each volunteer. After
species identification by classic biochemical tests and ABI 3130
system (Applied Biosystem, USA), 32 isolated strains of each
species were subjected to MIC determination by agar dilution
method provide by CLSI (document M7-A5 for aerobic bacterial
and document M11-A5 for anaerobic bacterial). The E. coli
ATCC25922 and E. faecalis ATCC 29212 were used as quality
control for MIC determination. The minimum concentration to
inhibit 50% of isolates (MIC50) and the minimum concentration
to inhibit 90% of isolates (MIC90) was calculated based on
the MIC distribution and estimated by probability analysis
using SPSS statistical package (Kays and Graff, 2002; Xu et al.,
2013).
Designation of Tulathromycin Dosage in
Preliminary Test
The preliminary test for selection of tulathromycin concentration
was carried out following the method in previous study (Hao
et al., 2013). Briefly, different concentrations of tulathromycin
(0, 0.5, 10, 20, 40, 60, 80, 100 µg/mL) were mixed with 50 mL
prepared fecal samples at the final concentration of 20% (w/v).
The activity of tulathromycin on populations of four different
bacteria (E. coli, Enterococcus, Bifidobacterium, and B. fragilis)
were determined by bacterial colony count using selective agars.
The highest concentration of tulathromycin was selected for
further experiments as it was able to significantly change the
population of four predominant intestinal bacteria.
The low to intermediate concentration of tulathromycin (0.1,
1, and 10 µg/mL) were designed based on the acceptable daily
intake (ADI) recommended by FDA (50 µg/kg.bw/d), EMA
(10.99 µg/kg.bw/d), and APVMA (5 µg/kg.bw/d). In those
designed concentration, 1 µg/mL tulathromycin was the mean
MIC50-value to the most sensitive Bifidobacterium strains. One
group was drug free methanol control (0 µg/mL tulathromycin).
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Establishment of Chemostats and the Time
Schedule
The establishment of chemostat models and the time schedule
were carried out following the method in previous studies
(Carman and Woodburn, 2001; Hao et al., 2013). Briefly, 50 mL
prepared fecal suspension at the final concentration of 20% (w/v)
was inoculated into each culture vessel. After 7 h incubation,
culture medium was pumped into and out of the culture vessel at
a uniform rate of 35mL/h tomaintain 500mL of culturemedium.
After 7 days running, the chemostats reached to a steady state.
From 7th to 13th day, the chemostats were kept on running
on steady state without administration of tulathromycin(Chen
et al., 2011, 2014). From 14th to 20th day, five designed
concentrations of tulathromycin (0, 0.1, 1, 10, and 100 µg/mL)
were, respectively, infused into the culturemedium. During 20th–
22nd day, the tulathromycin was withdrawn from chemostat
models and 1mL of 6× 108 CFU/mL (2XMcFarland) Salmonella
Typhimurium SI3 were daily inoculated into each chemostat.
Then the chemostats continued to run for another 7 days (to 29th
day) without challenge of Salmonella Typhimurium (Moffatt,
2007).
Monitoring Bacterial Counts in the
Chemostats
During day 7–20, samples were daily taken from each chemostat.
The changes of four predominant bacteria (E. coli, Enterococcus,
B. fragilis, and Bifidobacterium) were measured by viable cell
counting (Hao et al., 2013, 2015).
Monitoring Short Chain Fatty Acids
(SCFAs) in the Chemostats
During day 7–20, samples were daily taken from each chemostat.
The concentration of three primary SCFAs (acetic acid, butryric
acid, and propionic acid) were monitored using a developed gas
chromatographic (GC) method (Hao et al., 2013, 2015).
Evaluation of Colonization Resistance in
the Chemostats
From day 20th to 29th, samples were taken from each chemostat
to monitor the population of Salmonella Typhimurium SI3 using
bismuth sulfite (BS) agar containing 4 µg/mL ciprofloxacin(Sun
et al., 2011; Hao et al., 2013, 2015). The colonization resistance
was disrupted if Salmonella Typhimurium SI3 was successfully
colonized into chemostat models.
Monitoring Resistance Rate in the
Chemostats
During day 8–20, samples were daily taken from each chemostat.
The change of resistance rate was also monitored following the
method in previous study (Hao et al., 2013, 2015). The resistance
rates of E. coli and Enterococcus were equal to the number of
resistant colonies on the selective agars containing 4-fold MIC90
of tulathromycin divided by the number of total colonies on
the selective agars without tulathromycin. The 4-fold MIC90
was used for selection of tulathromycin resistance on basis of
VICH GL-36 document and some previous reports of resistance
selection (Allen and Bierman, 2009; Kadlec et al., 2011).
Determination of Resistance Pheno- and
Geno-type in the Selected E. faecalis
During day 8–20, a total of 70 Enterococcus isolates were random
selected from samples in the chemostat containing 100 µg/mL
tulathromycin. After species identification by biochemical tests
and PCR amplification, 64 isolates were identified as E. faecalis.
Among these E. faecalis, 34 isolates were obtained before the
administration of tulathromycin, while 30 isolates were selected
after the treatment with tulathromycin. The susceptibility of the
64 E. faecalis to macrolide, lincosamides, and tetracycline were
determined by agar dilution method.
The genes involved in macrolide-lincosamides-
streptogramins (MLS) resistance with a methylation mechanism
were determined by PCR amplification of known erm genes
using specific primers for ermA, ermB, and ermC (see Table 1).
The genes involved in antibiotic eﬄux systems were determined
using specific primers for the mefA/E gene (see Table 1). The
PCR procedure was followed the method in previous published
paper (Portillo et al., 2000).
Detect Transfer Risk of the Selected
Macrolide Resistant E. faecalis
The macrolide-resistant isolates containing ermB gene were
selected to determine the presence of transposons Tn1545 and
TABLE 1 | PCR primers and products for detection of macrolides
resistance gene and transposons and virulence determinants in
E. faecalis.
Primers 5′–3′ Target GeneBank
fragment (bp) no.
ermA F: GTTCAAGAACAATCAATACAGAG 421 FN668375
R: GGATCAGGAAAAGGACATTTTAC
ermB F: GAAAAGGTACTCAACCAAATA 639 NC_014498
R: AGTAACGGTACTTAAATTGTTTAC
ermC F: AATCGGCTCAGGAAAAGG 534 NC_014498
R: ATCGTCAATTCCTGCATG
mef (A/E) F: AGTATCATTAATCACTAGTGC 346 NC_018641
R: TTCTTCTGGTACTAAAAGTGG
Tn 1545 F: CTTAGAAGCAAACTTAAGAGTGTGT 382 NC_013644
R: GGTTGAGTA CCTTTTCATTCGTTAA
Tn 917 F: ATCTGACGGTGACATCTCTC 652 NC_017312
R: GGTTGAGTACCTTTTCATTCGTTAA
esp F: TTGCTAATGCTAGTCCACGACC 932 AF034779
R: GCGTCAACACTTGCATTGCCGA
gelE F: ACCCCGTATCATTGGTTT 405 M37185
R: ACGCATTGCTTTTCCATC
cylA F: GACTCGGGGATTGATAGGC 688 AD1CLYL
R: GCTGCTAAAGCTGCGCTTAC
ace F: GGAATGACCGAGAACGATGGC 616 AF159247
R: GCTTGATGTTGGCCTGCTTCCG
asal F: CCAGCCAACTATGGCGGAATC 529 SFPASA1
R: CCTGTCGCAAGATCGACTGTA
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Tn917 using the primers (see Table 1) and method established
in previous study (Okitsu et al., 2005). Filter mating method
was used to investigate the conjugative transfer of the selected
macrolide resistant E. faecalis. A representative macrolide-
resistant isolate containing ermB and composite transposon was
selected as donor strain. The recipients were two rifampicin-
resistant strains, E. faecalis JH2-2 (Rif MIC > 50 µg/mL)
and E. coli NK5449 (Rif MIC > 100 µg/mL). The donor and
recipient strains were mixed into the conjugation system at
the ratio of 1:9 and incubated on the serum agar for 48 h
at 37◦C. The number of donor, recipient and transconjugants
were counted by agar plate containing rifampicin and/or
erythromycin.
Determination of Virulence in the Selected
E. faecalis
The presence of virulence factors, including the surface
protein (esp), haemolysin activator (cylA), gelatinase
(gelE), collagen binding protein (ace), and aggregation
substances (asal), were determined by PCR in the 64
E. faecalis isolates obtained in the pre- and post-treatment
of tulathromycin in the chemostat. PCR primers used in this
study were listed in Table 1. The annealing temperatures
of five virulence factors were 65◦C for esp, 51◦C for gelE,
61◦C for CylA, 61◦C for ace and 63◦C for asal gene,
respectively.
In order to compare the changes of pathogenicity of E. faecalis,
two representative E. faecalis isolates (E. faecalis 143 and
E. faecalis 174) were subjected to determine the median lethal
dose (LD50). Briefly, the 72 SPF Kunming mice with body
weight of 25–28 g were randomly divided into nine groups
with half males and half females. The groups were, respectively,
challenged with E. faecalis isolate by intraperitoneal injection of
0.5 mL diluted concentration of bacteria suspension (107–1010
CFU/mouse). The dead mice were carefully dissected in a
bacteria-free operating environment. The LD50 was calculated
by improved Karber method. All experimental procedures were
performed according to the guidelines of the committee on
the use and care of the laboratory animals in Hubei province
China. The study was approved by the Animal Care Center,
Hubei Science and Technology Agency in China. All the animals
were monitored throughout the study for any sign of adverse
effect.
Statistical Analysis
All experiments were performed in triplicate. The statistical
analysis was performed following the previous study (Hao et al.,
2013, 2015). Briefly, a “mean pre-treatment” level and 95%
prediction interval (PI95) for each parameter was set up based
on the data obtained from each culture vessel during steady state
(day 7–13) and used as reference boundaries for assessing the
effect of tulathromycin on each parameter in the drug exposure
period (day 14–20).
NOAEC and mADI Calculation
The NOAEC was the no observable adverse effect concentration
in this study. Themicrobiological acceptable daily intake (mADI)
for tulathromycin was calculated following the guideline of VICH
GL-36. The formula used for mADI calculation was that mADI=
NOAEC × daily fecal bolus/(fraction of oral dose available for
micro-organisms× weight of human).
RESULTS
MIC90 of the Strains Isolated from Fresh
Fecal Samples
The 32 strains of each species (E. coli, Enterococcus,
Bifidobacterium, and B. fragilis) were isolated from fresh
fecal samples of six volunteers. The MIC for 90% of
isolates (MIC90) of tulathromycin for E. coli, Enterococcus,
Bifidobacterium, and B. fragilis were 5.53, 7.87, 1.35, and 2.30
µg/mL, respectively. After dilution, the methanol used for
dissolving tulathromycin did not exert some antimicrobial
effect.
The Designed Four Tulathromycin
Concentration
From the preliminary test, 100 µg/mL was the highest
concentration of tulathromycin which could significantly change
the population of four predominant intestinal bacteria. Based on
the ADI-values recommended by FDA, EMA, and APVMA, the
lower concentration of tulathromycin were designed as 0.1, 1, and
10 µg/mL.
Effect of Tulathromycin on Bacterial
Counts
The population of E. coli was kept between 3.667 × 106
and 5.482 × 106 CFU/mL in steady state based on statistical
data among five chemostats (Figure 1A). Three days after
administration of 100 µg/mL tulathromycin, the population of
E. coli was decreased to 6.556× 105 CFU/mL which was∼6-fold
lower than 95% lower confidence limit. However, the three low
concentration of tulathromycin (0.1, 1, and 10 µg/mL) did not
significantly change the number of E. coli.
Pre-treatment of tulathromycin (day 8–13), the Enterococcus
counts was in the range of 9.526 × 104–8.674 × 105 CFU/mL
(Figure 1B). Under exposure to 10 µg/mL tulathromycin,
Enterococcus count was decreased ∼1.6-fold in the 5th day
of post-treatment. On the contrary, the total number of
Enterococcus was increased almost 3-fold from 18th day after
administration of 100 µg/mL tulathromycin.
The number of Bifidobacterium varied from 1.105 ×
107 to 2.70 × 108 CFU/mL (Figure 1C) during day 8–13.
The administration of 100 µg/mL tulathromycin significantly
decreased the number of Bifidobacterium in the chemostat. It was
shown that Bifidobacterium count was decreased ∼10-fold lower
than 95% lower confidence limit.
Significant and dose-dependent effects of tulathromycin on
B. fragilis counts were observed in all tested concentration
of tulathromycin. After treatment by 10 and 100 µg/mL
tulathromycin, B. fragilis count was decreased 6- and 90-
fold lower than 95% lower confidence limit, respectively
(Figure 1D).
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FIGURE 1 | Effect of tulathromycin on Escherichia coli (A),
Enterococcus (B), Bifidobacterium (C), Bacteroides fragilis (D) in
chemostat model. , 0 µg/ mL; 1, 0.1 µg/ mL; N, 1 µg/mL; , 10 µg/mL;
, 100 µg/mL; ---------------, pre-treatment mean; - - - - - - - -, 95% predicated
interval.
Effect of Tulathromycin on Short Chain
Fatty Acid (SCFA)
The relative low concentration of tulathromycin (0, 0.1, and 1
µg/mL) did not significantly change the molar concentration
of acetic acid, propionc acid and butyric acid (Figure 2).
Under exposure to 10 µg/mL tulathromycin, the concentration
of acetic acid and propionc acid was slightly decreased.
Upon the administration of 100 µg/mL tulathromycin, the
concentration of acetic acid, propionc acid, and butyric acid
were decreased ∼1.3, 1.3, and 2.68-fold lower than 95% lower
FIGURE 2 | Effect of tulathromycin on acetic acid (A), propionic acid
(B), butyric acid (C) in chemotat models. , 0 µg/mL; 1, 0.1 µg/mL; N, 1
µg/mL; , 10 µg/mL; , 100 µg/mL; ---------------, pre-treatment mean;
- - - - - - - -, 95% predicated interval.
confidence limit, respectively. Among the three dominant SCFAs,
the concentration of propionc acid was changed remarkably
under exposure of tulathromycin and present significant dose-
dependent effect of tulathromycin.
Effect of Tulathromycin on Colonization
Resistance
In the single growth control group, the growth of Salmonella
Typhimurium was stable at the level of 3.75 × 107–1.54 ×
108 CFU/mL, indicating that Salmonella Typhimurium grew
well in the chemostat model containing no drug and gut
microbiome (Figure 3). However, the colony number of
Salmonella Typhimurium tapered to 102 CFU/mL on day 31
in the chemostat containing stable gut microbiome, suggesting
that the gut microbiome may establish colonization resistance to
exogenous pathogens. After treatment of lower concentration of
tulathromycin (10, 1, and 0.1 µg/mL), the number of Salmonella
Typhimurium was also decreased to the level of 102 CFU/mL. In
contrast, the colonization number of Salmonella Typhimurium
was in the range of 2.08× 105–7.15× 106 CFU/mL in
the chemostat administrated by highest concentration
of tulathromycin (100 µg/mL), suggesting that the high
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concentration of drug may disturb the colonization
resistance of gut microbiome and induce the proliferation of
pathogen (Figure 3).
Effect of Tulathromycin on Resistant Rate
Before the treatment of tulathromycin, 10–30% of tulathromycin
resistance was observed in Escherichia coli and in Enterococcus
strains (Figures 4A,B). Under exposure to 10 µg/mL
tulathromycin, the percentage of resistant Enterococcus was
slight increased (Figure 4B). After treatment with 100 µg/mL
tulathromycin, the resistant rates in E. coli and Enterococcuswere
obviously higher than control group, especially in Enterococcus,
it reach up to 80% (Figures 4A,B). After administration of
different concentration of tulathromycin, regular changes
were not observed in Bifidobacterium and Bacteroides fragilis
(Figures 4C,D).
Resistant Phenotype and Genotype of the
Selected E. faecalis
After species confirmation, 34 and 30 E. faecalis isolates were
selected from chemostats pre- and post-treatment, respectively.
The MIC50 and MIC90 of these 64 E. faecalis strains to
erythromycin, tulathromycin, lincomycin, and tetracycline
were showed in Table 2. The 34 E. faecalis strains isolated
from chemostats before administration of tulathromycin
exhibited high susceptibility to erythromycin, tulathromycin
and tetracycline (MIC ≤ 4 µg/mL), and low resistance to
lincomycin (MIC = 16, 32 µg/mL). However, after treatment
with tulathromycin, 30 E. faecalis isolates (except for the strains
of 141, 142, 144, and 164) showed high-level resistance to the four
tested antibiotics (MIC≥ 4µg/mL). TheMIC50 of erythromycin,
tulathromycin, lincomycin, and tetracycline to E. faecalis were
considerably increased for 88.9, 49.8, 5.1, and 45.4-fold,
respectively.
About 88.46% of the tulathromycin resistant E. faecalis
isolated from chemostats harbored macrolide resistance
associated gene of ermB (Table 3). However, the tested macrolide
resistance associated genes (ermABC and mefA/E) were free in
the tulathromycin resistant E. faecalis strains (Table 3).
FIGURE 3 | Growth curves of Salmonella Typhimurium in chemostat
models. , 0 µg/mL; 1, 0.1 µg/mL; N, 1 µg/mL; , 10 µg/mL; , 100 µg/
mL; •, growth control.
Transfer Risk of Macrolide Resistant
E. faecalis
All of ermB containing E. faecalis strains also harbored composite
transposon of Tn1545 (Table 3). When the E. faecalis 143 strain
containing both ermB and Tn1545 was selected as donor strain
and subjected to conjugation transfer test, the result showed
that macrolide resistant determinants could transfer to E. faecalis
JH2-2 and E. coli NK5449 at the frequencies of 10−6–10−7
(Table 4).
FIGURE 4 | Effect of tulathromycin on resistance in Escherichia coli (A),
Enterococcus (B), Bifidobacterium (C), Bacteroides fragilis (D) in
chemostat model. , 0 µg/mL; 1, 0.1 µg/mL; N, 1 µg/mL; , 10 µg/ mL;
, 100 µg/ mL; ---------------, pre-treatment mean; - - - - - - - -, 95%predicated
interval.
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TABLE 2 | Comparison of MICs of separated E. faecalis strains, before and after treated with four drugs.
Drug Pre- or post-treatment Strains (N) MICs (µg/mL) MIC50 (µg/mL) MIC90 (µg/mL)
256 128 64 32 16 8 4 2 1 0.5 0.25
ERY Pre- 34 1 2 26 4 1 2.610 5.211
ERY Post- 30 17 9 3 1 231.698 —
TLU Pre- 34 31 2 1 4.904 10.995
TLU Post- 30 21 4 3 2 244.149 —
LIN Pre- 34 27 6 1 41.706 221.77
LIN Post- 30 21 1 2 6 213.721 669.13
TET Pre- 34 33 1 2.552 4.437
TET Post- 30 22 2 5 1 115.681 —
MIC50 = minimum concentration to inhibit 50% of isolates; MIC90 = minimum concentration to inhibit 90% of isolates. MIC90- and MIC50-values are estimated values by probability
analysis by SPSS (Kays and Graff, 2002; Xu et al., 2013); “—” datas not given; white areas was pre-treatment group; gray areas was post-treatment group; ERY, erythromycin; TLU,
tulathromycin; LIN, lincomycin tetracycline.
TABLE 3 | The relationship of MIC, resistant gene and virulence gene in E. faecalis isolated during drug administration.
Isolates no. MICs Resistant gene Virulence determinants
ERY TLU LIN TET ermB Tn1545 esp cylA gelE ace
141 2 4 32 2 – – – – + +
142 2 4 32 2 – – – – + +
143 128 256 256 128 + + + + – +
144 2 4 32 2 – – – – + +
145 256 256 32 2 – + – – + +
151 128 256 256 128 + – + + – +
152 128 128 256 128 + + + + – +
154 1 2 32 2 – – – – + +
155 128 128 32 0.5 – – – – + +
161 256 256 256 128 + + + + – +
162 256 256 256 128 + + + + – +
164 256 256 256 128 + + + + – +
165 256 256 256 128 + + + + – +
171 256 256 256 128 + + + + – +
172 128 256 64 64 + – – – – –
174 256 256 64 64 – + – – – –
181 128 256 256 128 + + + + – +
182 256 256 256 128 + + + + – +
183 256 256 256 128 + + + + – +
185 256 256 256 128 + + – – – –
191 128 256 256 128 + + + + – +
192 128 128 256 128 + + + + – +
193 256 256 256 128 + + + + – +
194 256 256 256 128 + + + + – +
195 256 256 256 128 + + + + – +
201 128 128 128 128 + + + + – +
202 256 256 256 128 + + + + – +
203 256 256 256 128 + + + + – –
204 256 256 256 128 + + + + – +
205 256 256 256 128 + + + + – +
The isolate was numbered by isolated day and strain number. For example, isolate 143 was the third isolate obtained in 14th day. Gray shades used to distinct the positive and negative
of special virulence factor.
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TABLE 4 | The frequencies of conjugation transfer between donor and host strains.
Receptor strains Times Donor strain (CFU/mL) Host strain (CFU/mL) Transconjugant (CFU/mL) Transfer frequency
E. faecalis JH2-2 1 1.21 × 109 2.62 × 108 2.04 × 103 7.79 × 10−6
2 4.30 × 109 6.75 × 108 9.40 × 102 1.39 × 10−6
3 3.72 × 109 4.35 × 108 2.60 × 103 5.98 × 10−6
E. coli NK5449 1 8.42 × 108 6.82 × 108 1.90 × 102 2.79 × 10−7
2 1.25 × 109 3.71 × 108 2.20 × 102 5.93 × 10−7
3 1.13 × 109 1.65 × 108 6.60 × 102 4.00 × 10−6
FIGURE 5 | Comparison of positive rate of resistant determinants and
virulence genes of E. faecalis before and after experiment with drug.
Virulence of the Selected E. faecalis
In the 34 E. faecalis stains selected in the pre-treatment, positive
ratios of esp, gelE, clyA, ace, and asalwere 0, 61.76, 0, 58.8% and 0,
respectively. However, these changed into 70, 20, 70, 83.3% and
0, respectively, in the 30 E. faecalis stains selected in the post-
treatment (Figure 5). The positive rates of surface protein (esp)
and hemolysin activator (cylA) were significantly increased (0–
70%). To the contrary, the carriage ratios of gelatinase (gelE) had
a downside (61.76–20%). Aggregation substances (asal) were not
found in all of the 64 strains E. faecalis. As shown in Table 3,
most of the antimicrobial resistance in E. faecalis selected after
treating with tulathromycin carried resistance gene of ermB,
transferable element of Tn1545 and three virulence gens (esp,
cylA, and ace).
After infection with E. faecalis 143 (harboring ermB, Tn1545,
esp, cylA, and ace), mice died within 8 h which was earlier
than the death of mice infected with E. faecalis 174 (free of
ermB, esp, cylA, and ace). The LD50 of the two E. faecalis
strains was calculated by improved Karber method. The detailed
results were shown in Table 5. The LD50 E. faecalis 143
(5.970 × 109 µg/mL) was three-times higher than that of
E. faecalis 174(1.603 × 109 µg/mL), suggesting that E. faecalis
143 strain harboring virulence factors (esp, cylA, and ace) was
more virulent than the strain without these two virulence
genes.
NOAEC and mADI Calculation
Based on our results, the NOAEC was set up as 1 µg/mL. The
daily fecal bolus was known as 220 mL. The fraction of oral
dose available for microorganisms in the intestinal tract was 0.25
which can be split into two factors of 0.5 each. One factor of
0.5 was based on results for reduced availability of the substance
due to interaction with fecal matter (EMEA, 2004) and the other
factor of 0.5 was based on the impact of acidic colonic pH on
tulathromycin availability for gut bacteria(USFDA, 2004). The
weight of human was 60 kg/person. Therefore, our established
mADI was 14.66 µg/kg.bw/d.
DISCUSSION
This study is the first of its kind to assess the effect of
tulathromycin on human microbiota using the chemostat model.
In addition, this study concentrated on the antimicrobial
resistance development and virulence change of E. faecalis
isolates in chemostats under long term exposure to a range of
tulathromycin concentrations.
The present study showed that the intermediate concentration
(10 µg/mL) slightly change the population of Enterococci and
Bacteroides fragilis, while the highest concentration (100 µg/mL)
inhibited the growth of three type of bacteria except for
Enterococcus. This result was similar with our previous results
that the numbers of some intestinal bacteria (e.g., B. fragilis)
underwent significant changes during exposure to tilmicosin
(Hao et al., 2015). As one of the most predominant bacteria
in the intestinal microbiota, B. fragilis may be a most sensitive
indicator of gut microbiome under exposure to macrolide drugs
including erythromycin, tilmicosin, and tulathromycin (Carman
et al., 2005; Merck sharp and D. Corp., 2011; Hao et al.,
2015).
The present study and our previous investigation suggested
that in the chemostat model high concentration of macrolide
drugs (tilmicosin and tulathromycin) could significantly reduce
the population of B. fragilis and subsequently resulted into
the decline of the three main SCFAs especially propionic
acid (Hao et al., 2015). The related change of propionic
acid with B. fragilis population that we found was also
observed in human flora associated (HFA) mice model (MacNeil,
2005).
Similar to previous studies, the colonization resistance of
human intestinal microbiota in the chemostat was disrupted
Frontiers in Microbiology | www.frontiersin.org 8 April 2016 | Volume 7 | Article 477
Hao et al. Microbiological Safety of Tulathromycin
TABLE 5 | Comparing the LD50 of E. faecalis 143 and 174 in the mice experiment.
E. faecalis no. Inoculated dose (CFU/mouse) Total mice number Dead mice number during experiment lgLD50 LD50 (CFU/mL)
0–8 h 8–24 h 24–48 h >48 h
14-3 1.60 × 1010 8 7 0 0 0 9.205 1.603 × 109
1.60 × 109 8 3 1 1 0
1.60 × 108 8 0 0 0 0
1.60 × 107 8 0 0 0 0
0 8 0 0 0 0
17-4 1.06 × 1010 8 2 1 1 0 9.776 5.970 × 109
1.06 × 109 8 0 0 1 0
1.06 × 108 8 0 0 0 0
1.06 × 107 8 0 0 0 0
0 8 0 0 0 0
under 7 days exposure to high concentration of antibiotics
(Carman et al., 2004; Hao et al., 2013). Coincidently, in
our chemostat model, there were significant alterations
in the populations of E. coli, B. fragilis, Enterococcus,
and Bifidobacterium which appeared to be indicator of
intestinal microbiota and contributed a lot to the colonization
resistance (Corpet, 1993; Nuding et al., 2013). As previously
reported, 105 CFU/mL of E. coli had a complete inhibitory
effect on the growth of Salmonella (Carman et al., 2004).
However, in our previous result, the treatment of tilmicosin
did change the colonization resistance (Hao et al., 2015).
This difference suggested that disruption of colonization
resistance was largely depended on antimicrobial agents and
their concentrations (Carman et al., 2004; Ferreira et al.,
2011).
Similar to previous results, resistance rate in E. coli did not
change in the chemostat and HFA rodent models treated by
tilmicosin (EMEA, 1997; Cerniglia and Kotarski, 2005; Hao
et al., 2015). This may be due to the inherent resistance
to macrolide drugs in E. coli (Phuc Nguyen et al., 2009).
However, the resistance rate of Enterococcus, Bifidobacterium,
and B. fragilis was significantly increased under the selective
pressure of 100 and 10 µg/mL tulathromycin in our study.
Consistently, the subtherapeutic and therapeutic administration
of tulathromycin also significantly increased the proportion of
erythromycin resistant enterococci in beef cattle (Zaheer et al.,
2013).
Our study showed that most of the isolated tulathromycin
resistant enterococcicontained ermB. The ermB gene in different
gram-positive bacteria has been well-documented (Schmitz et al.,
2000; Perreten et al., 2005; Littauer et al., 2006; Tremblay
et al., 2011; Zmantar et al., 2011). The occurrence of macrolide
resistance mediated by ermB was also found in enterococci
originating from swine and cattle due to the subtherapeutic use
of tylosin and tulathromycin (Jackson et al., 2004; Chen et al.,
2008; Zaheer et al., 2013).
Tn1545 was found in almost of the high-level macrolides
resistant Enterococcus harboring ermB gene. Our conjugation
test also showed that the Enterococcus isolate containing Tn1545
and ermB can transfer its resistance to E. faecalis JH2-2 and E.
coli NK5449. The transferability of ermB located in transposon
may play an important role on the increase of resistance rate in
Enterococcus, Bifidobacterium, and B. fragilis (Okitsu et al., 2005;
Ciric et al., 2013).
Both the previous study and our study found that gelE gene
was one of the predominant virulence genes in E. faecalis
(Di Rosa et al., 2006). A positive correlation between
macrolide resistance and gelE virulence gene was observed
in an epidemiological investigation (Zou et al., 2011; Lins
et al., 2013). High level expression of gelE has also been
observed in multi-drug resistant Enterococci and in macrolide
resistant E. feacalis containing ermB gene (Arciola et al.,
2008; Hao et al., 2015). However, the E. feacalis containing
both ermB gene and gelatinase (gelE) did not occur in our
study.
Most of E. faecalis harboring both virulence factors (esp and
cylA) and resistance gene of ermB were selected after treatment
with tulathromycin, however, no E. faecalis isolates containing
these two virulence genes was found before tulathromycin
treatment. Coincidently, recent studies also found the existence
of a large pool of potentially virulent and multidrug resistant
E. faecalis in diseased farm animals (Seputiene et al., 2012).
The presence and expression of some virulence determinants
(e.g., esp and cylA) may enhance the colonization and
invasion of E. faecalis to the epithelial cell of host (Trieu-
Cuot et al., 1990; Littauer et al., 2006; Heikens et al., 2009;
Johanson et al., 2012; Cafini et al., 2015; Kafil and Mobarez,
2015). The acute toxicity test with SPF mice indicated that
E. faecalis harboring the macrolide resistant gene of ermB and
two virulence genes (esp and cylA) had higher toxicity and
pathogenicity.
Our established mADI (14.6 µg/kg.bw/d) was slightly higher
than the mADI (10.97 µg/kg.bw/d) recommended by EMA-
CVMP and the mADI (5 µg/kg.bw/d) recommended APVMA.
Recently, EMA-CVMP revised the mADI of tulathromycin to 55
µg/kg.bw/d (EMA/CVMP, 2015). As a new approved drug, more
work of safety assessment needs to be done to establish the final
mADI of tulathromycin.
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EXECUTIVE SUMMARY
Dose dependent effect on colonization resistance
10 µg/mL tulathromycin would significantly decrease the
population but increase the resistance rate of Enterococcus and
Bacteroides fragilis.
100 µg/mL tulathromycin significantly decreased population of
Escherichia coli, Bifidobacterium and B. fragilis and SCFAs.
The colonization resistance was disturbed by higher
concentration of tulathromycin.
Antimicrobial resistance inducement and risk of resistant
factors
10 µg/mL tulathromycin would significantly increase the
resistance rate of Enterococcus and Bacteroides fragilis.
100 µg/mL tulathromycin largely increased resistant rate of
Enterococcus and selected multidrug resistant E. faecalis.
The selected resistant E. faecalis always carried ermB gene. It
was located in transposons Tn1545 and had ability of
horizontal gene transfer (HGT).
The virulence change under drug exposure
The E. faecalis harboring resistance gene of ermB gene and
virulence gene of esp and cylA was only selected after
administration of high concentration of tulathromycin.
The E. faecalis harboring esp and cylA had higher pathogenicity.
Microbiological acceptable daily intake (mADI) of
tulathromycin
The mADI was calculated as 14.66 µg/kg bw/day based on our
study.
CONCLUSIONS
In conclusion, the established NOAEC and mADI in our
study was 1 µg/mL and 14.66 µg/kg.bw/day, respectively.
The low concentration of tulathromycin had no significant
microbiological hazard with regard to colonization resistance
and antimicrobial resistance. However, the long-term exposure to
high concentration of tulathromycin (100 µg/mL) may damage
the colonization resistance of human gut microbiota and induce
the development of antimicrobial resistance in Enterococcus. The
E. feacalis containing both transferable resistance determinant
(ermB in Tn1545) and virulence genes (esp and cylA) were
selected after administration of high level tulathromycin. More
work need to be done to systematically assessment the safety of
tulathromycin on human public health.
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